0001209191-17-055830.txt : 20171004
0001209191-17-055830.hdr.sgml : 20171004
20171004162226
ACCESSION NUMBER: 0001209191-17-055830
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171002
FILED AS OF DATE: 20171004
DATE AS OF CHANGE: 20171004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Herberts Curt A. III
CENTRAL INDEX KEY: 0001691262
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 171121913
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
STREET 2: POINT RICHMOND TECH CENTER
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-02
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001691262
Herberts Curt A. III
C/O SANGAMO THERAPEUTICS, INC.
POINT RICHMOND TECH CTR, 501 CANAL BLVD.
RICHMOND
CA
94804
0
1
0
0
Sr.VP & Chief Business Officer
Common Stock
2017-10-02
4
M
0
5830
5.41
A
21663
D
Common Stock
2017-10-02
4
S
0
5830
15.00
D
15833
D
Common Stock
2017-10-02
4
M
0
5416
8.87
A
21249
D
Common Stock
2017-10-02
4
S
0
5416
15.00
D
15833
D
Common Stock
2017-10-02
4
M
0
3754
9.41
A
19587
D
Common Stock
2017-10-02
4
S
0
3754
16.00
D
15833
D
Stock Option (Right to Buy)
5.41
2017-10-02
4
M
0
5830
0.00
D
2022-12-05
Common Stock
5830
0
D
Stock Option (Right to Buy)
8.87
2017-10-02
4
M
0
5416
0.00
D
2025-07-26
Common Stock
5416
4584
D
Stock Option (Right to Buy)
9.41
2017-10-02
4
M
0
3754
0.00
D
2025-12-07
Common Stock
3754
33746
D
All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
The shares underlying the stock option are fully vested and exercisable.
One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the July 27, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
One-quarter (1/4) of the option shares will vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
/s/ Florence Tam, Attorney-in-Fact
2017-10-03